TSC2 c.290C>T ;(p.A97V)

Variant ID: 16-2103407-C-T

NM_000548.3(TSC2):c.290C>T;(p.A97V)

This variant was identified in 5 publications

View GRCh38 version.




Publications:


Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.

Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research
Zhao, Ming M; Scott, Stephen S; Evans, Kurt W KW; Yuca, Erkan E; Saridogan, Turcin T; Zheng, Xiaofeng X; Wang, Heping H; Korkut, Anil A; Cruz Pico, Christian X CX; Demirhan, Mehmet M; Kirby, Bryce B; Kopetz, Scott S; Diala, Irmina I; Lalani, Alshad S AS; Piha-Paul, Sarina S; Meric-Bernstam, Funda F
Publication Date: 2021-03-15

Variant appearance in text: TSC2: A97V
PubMed Link: 33414137
Variant Present in the following documents:
  • Main text
View BVdb publication page



Integrated molecular drivers coordinate biological and clinical states in melanoma.

Nature Genetics
Conway, Jake R JR; Dietlein, Felix F; Taylor-Weiner, Amaro A; AlDubayan, Saud S; Vokes, Natalie N; Keenan, Tanya T; Reardon, Brendan B; He, Meng Xiao MX; Margolis, Claire A CA; Weirather, Jason L JL; Haq, Rizwan R; Schilling, Bastian B; Stephen Hodi, F F; Schadendorf, Dirk D; Liu, David D; Van Allen, Eliezer M EM
Publication Date: 2020-12

Variant appearance in text: TSC2: 290C>T; A97V
PubMed Link: 33230298
Variant Present in the following documents:
  • NIHMS1637640-supplement-SuppData1.xlsx, sheet 1
View BVdb publication page



High prevalence of the MLH1 V384D germline mutation in patients with HER2-positive luminal B breast cancer.

Scientific Reports
Lee, Seung Eun SE; Lee, Hye Seung HS; Kim, Kyoung-Yeon KY; Park, Jung-Hoon JH; Roh, Hanseong H; Park, Ha Young HY; Kim, Wan-Seop WS
Publication Date: 2019-07-29

Variant appearance in text: TSC2: A97V
PubMed Link: 31358837
Variant Present in the following documents:
  • 41598_2019_47439_MOESM2_ESM.xlsx, sheet 5
View BVdb publication page



Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board.

Jco Precision Oncology
Dalton, W Brian WB; Forde, Patrick M PM; Kang, Hyunseok H; Connolly, Roisin M RM; Stearns, Vered V; Gocke, Christopher D CD; Eshleman, James R JR; Axilbund, Jennifer J; Petry, Dana D; Geoghegan, Cindy C; Wolff, Antonio C AC; Loeb, David M DM; Pratilas, Christine A CA; Meyer, Christian F CF; Christenson, Eric S ES; Slater, Shannon A SA; Ensminger, Jennifer J; Parsons, Heather A HA; Park, Ben H BH; Lauring, Josh J
Publication Date: 2017

Variant appearance in text: TSC2: A97V
PubMed Link: 30003184
Variant Present in the following documents:
  • Main text
View BVdb publication page



A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma.

Cancers
Mahalingam, Devalingam D; Goel, Sanjay S; Aparo, Santiago S; Patel Arora, Sukeshi S; Noronha, Nicole N; Tran, Hue H; Chakrabarty, Romit R; Selvaggi, Giovanni G; Gutierrez, Andres A; Coffey, Matthew M; Nawrocki, Steffan T ST; Nuovo, Gerard G; Mita, Monica M MM
Publication Date: 2018-05-25

Variant appearance in text: TSC2: A97V
PubMed Link: 29799479
Variant Present in the following documents:
  • cancers-10-00160-s001.pdf
View BVdb publication page